VerICiguaT Global Study in Subjects With Heart Failure With Reducd Ejection Fraction (VICTORIA) is a randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC simulator Vericiguat in subjects with heart failure with reduced ejection fraction (HFrEF)

Data Sharing

VICTORIA Data Sharing Charter (PDF)

Find more information about the VICTORIA study here.